JP2020536854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536854A5 JP2020536854A5 JP2020517328A JP2020517328A JP2020536854A5 JP 2020536854 A5 JP2020536854 A5 JP 2020536854A5 JP 2020517328 A JP2020517328 A JP 2020517328A JP 2020517328 A JP2020517328 A JP 2020517328A JP 2020536854 A5 JP2020536854 A5 JP 2020536854A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- medicament according
- subject
- semaguruchido
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022112446A JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17196254.1 | 2017-10-12 | ||
| EP17196254 | 2017-10-12 | ||
| PCT/EP2018/077654 WO2019072941A1 (en) | 2017-10-12 | 2018-10-10 | SEMAGLUTIDE IN MEDICAL THERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112446A Division JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536854A JP2020536854A (ja) | 2020-12-17 |
| JP2020536854A5 true JP2020536854A5 (https=) | 2021-07-29 |
| JP7148605B2 JP7148605B2 (ja) | 2022-10-05 |
Family
ID=60083831
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517328A Active JP7148605B2 (ja) | 2017-10-12 | 2018-10-10 | 医学療法におけるセマグルチド |
| JP2022112446A Active JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022112446A Active JP7475398B2 (ja) | 2017-10-12 | 2022-07-13 | 医学療法におけるセマグルチド |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US12029779B2 (https=) |
| EP (1) | EP3694538A1 (https=) |
| JP (2) | JP7148605B2 (https=) |
| KR (1) | KR20200069316A (https=) |
| CN (4) | CN119838000A (https=) |
| AU (2) | AU2018348929B2 (https=) |
| BR (1) | BR112020006246A2 (https=) |
| CA (1) | CA3078652A1 (https=) |
| CL (1) | CL2020000812A1 (https=) |
| IL (3) | IL322969A (https=) |
| MA (1) | MA50358A (https=) |
| MX (3) | MX2020003049A (https=) |
| MY (1) | MY204827A (https=) |
| PH (1) | PH12020550185A1 (https=) |
| SG (1) | SG11202002841PA (https=) |
| TW (1) | TWI842681B (https=) |
| WO (1) | WO2019072941A1 (https=) |
| ZA (3) | ZA202503350B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3078652A1 (en) * | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| CN115484935A (zh) | 2020-02-14 | 2022-12-16 | G2G生物公司 | 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物 |
| JP7761567B2 (ja) * | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
| US11478533B2 (en) * | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| WO2022212271A1 (en) * | 2021-03-29 | 2022-10-06 | Sanford Health | Methods and compositions for treating lysosomal storage disorders |
| CN119317635A (zh) * | 2022-06-08 | 2025-01-14 | 载度思生命科学有限公司 | 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器 |
| WO2024249659A2 (en) * | 2023-05-30 | 2024-12-05 | The Medical College Of Wisconsin, Inc. | Methods for weight loss and/or reducing weight gain |
| US12597496B2 (en) * | 2023-06-05 | 2026-04-07 | Closed Loop Medicine Ltd. | Dosing of incretin pathway drugs |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| WO2003002136A2 (en) | 2001-06-28 | 2003-01-09 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| DK3300721T4 (da) | 2003-11-20 | 2025-03-03 | Novo Nordisk As | Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger |
| MX2007005521A (es) | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN104324362B (zh) | 2005-09-14 | 2018-04-24 | 曼金德公司 | 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法 |
| KR101438839B1 (ko) | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제 |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| CA2677852A1 (en) | 2007-03-20 | 2008-09-25 | Nippon Kayaku Kabushiki Kaisha | Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| PT2373681T (pt) | 2008-12-10 | 2017-04-11 | Glaxosmithkline Llc | Composições farmacêuticas de albiglutida |
| AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
| WO2012016419A1 (zh) | 2010-08-06 | 2012-02-09 | 浙江贝达药业有限公司 | Glp-1衍生物及其应用 |
| SI2651398T1 (en) | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| WO2012088379A2 (en) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| WO2012177929A2 (en) | 2011-06-24 | 2012-12-27 | Amylin Pharmaceuticals, Inc. | Methods for treating diabetes with extended release formulations of glp-1 receptor agonists |
| PT2753312T (pt) | 2011-09-08 | 2017-02-03 | Mereo Biopharma 2 Ltd | Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas |
| EP2846823B1 (en) * | 2012-05-08 | 2019-12-04 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| EP4338805B1 (en) | 2012-06-29 | 2025-06-04 | Amarin Pharmaceuticals Ireland Limited | Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy |
| EP2866825B1 (en) | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| KR102272671B1 (ko) * | 2013-05-02 | 2021-07-06 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| UA127495C2 (uk) | 2015-12-23 | 2023-09-13 | Амджен Інк. | Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить |
| JP2020529440A (ja) | 2017-08-04 | 2020-10-08 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 糖尿病および関連する状態の処置におけるガボキサドールの使用 |
| CA3078652A1 (en) | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
-
2018
- 2018-10-10 CA CA3078652A patent/CA3078652A1/en active Pending
- 2018-10-10 BR BR112020006246-4A patent/BR112020006246A2/pt not_active Application Discontinuation
- 2018-10-10 WO PCT/EP2018/077654 patent/WO2019072941A1/en not_active Ceased
- 2018-10-10 KR KR1020207012311A patent/KR20200069316A/ko active Pending
- 2018-10-10 AU AU2018348929A patent/AU2018348929B2/en active Active
- 2018-10-10 JP JP2020517328A patent/JP7148605B2/ja active Active
- 2018-10-10 IL IL322969A patent/IL322969A/en unknown
- 2018-10-10 MA MA050358A patent/MA50358A/fr unknown
- 2018-10-10 SG SG11202002841PA patent/SG11202002841PA/en unknown
- 2018-10-10 CN CN202510084667.2A patent/CN119838000A/zh active Pending
- 2018-10-10 CN CN201880066425.9A patent/CN111212657A/zh not_active Withdrawn
- 2018-10-10 IL IL322968A patent/IL322968A/en unknown
- 2018-10-10 EP EP18788709.6A patent/EP3694538A1/en active Pending
- 2018-10-10 MY MYPI2020001658A patent/MY204827A/en unknown
- 2018-10-10 CN CN202411858188.3A patent/CN119950682A/zh active Pending
- 2018-10-10 CN CN202510086779.1A patent/CN120241968A/zh active Pending
- 2018-10-10 MX MX2020003049A patent/MX2020003049A/es unknown
- 2018-10-12 TW TW107136028A patent/TWI842681B/zh active
-
2020
- 2020-03-19 MX MX2025002188A patent/MX2025002188A/es unknown
- 2020-03-19 MX MX2025002189A patent/MX2025002189A/es unknown
- 2020-03-20 IL IL273470A patent/IL273470A/en unknown
- 2020-03-27 CL CL2020000812A patent/CL2020000812A1/es unknown
- 2020-03-27 PH PH12020550185A patent/PH12020550185A1/en unknown
- 2020-04-09 US US16/844,552 patent/US12029779B2/en active Active
-
2022
- 2022-07-13 JP JP2022112446A patent/JP7475398B2/ja active Active
-
2024
- 2024-06-07 US US18/736,608 patent/US20240316159A1/en not_active Abandoned
- 2024-08-30 US US18/820,792 patent/US12295988B2/en active Active
-
2025
- 2025-04-09 US US19/174,121 patent/US12551536B2/en active Active
- 2025-04-22 ZA ZA2025/03350A patent/ZA202503350B/en unknown
- 2025-04-22 ZA ZA2025/03388A patent/ZA202503388B/en unknown
- 2025-04-22 ZA ZA2025/03387A patent/ZA202503387B/en unknown
- 2025-05-15 AU AU2025203535A patent/AU2025203535A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536854A5 (https=) | ||
| CN115135304B (zh) | Glp-1组合物及其用途 | |
| JP6141958B2 (ja) | 増殖性疾患の治療のための併用療法（ベムラフェニブ及びｍｄｍ２阻害剤） | |
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2015187125A5 (https=) | ||
| JP2018531938A5 (https=) | ||
| RU2008138381A (ru) | Режимы дозирования адреналина | |
| RU2012148710A (ru) | Органическое соединение для применения при лечении рака печени | |
| RU2018121615A (ru) | Модуляторы активности комплемента | |
| Duems-Noriega et al. | Subcutaneous fluid and drug delivery: safe, efficient and inexpensive | |
| CN101347408B (zh) | 青藤碱静脉输液制剂 | |
| JP7291632B2 (ja) | 夜間頻尿治療剤 | |
| US10821126B2 (en) | Agent for treating retinopathy | |
| BRPI0510895A (pt) | formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t | |
| ES3062720T3 (en) | Sublingual epinephrine tablets | |
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| WO2011097148A3 (en) | Use of oral heparin preparations to treat urinary tract diseases and conditions | |
| EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
| JP2005512946A5 (https=) | ||
| JP2009506043A5 (https=) | ||
| RU2012126101A (ru) | Полипептидный конъюгат | |
| JP2019535830A5 (https=) | ||
| US20180289708A1 (en) | Low dose oral dipyridamole compositions and uses thereof | |
| Park | Novel route of insulin delivery using an implant-mediated drug delivery system | |
| CN108430581A (zh) | 用于利扎曲普坦的药物组合物 |